Spizzo Gilbert, Went Philip, Dirnhofer Stephan, Obrist Peter, Moch Holger, Baeuerle Patrick A, Mueller-Holzner Elisabeth, Marth Christian, Gastl Guenther, Zeimet Alain G
Division of Hematology and Oncology, Innsbruck Medical University, Austria.
Gynecol Oncol. 2006 Nov;103(2):483-8. doi: 10.1016/j.ygyno.2006.03.035. Epub 2006 May 6.
Currently available clinical and molecular factors provide still an insufficient prognostic and predictive assessment for patients with epithelial ovarian cancer (EOC). To identify a potential molecular target and prognostic/predictive factor for EOC, we investigated in a retrospective study the prognostic value of Ep-CAM overexpression in EOC.
We assessed by immunohistochemistry the expression of the Ep-CAM antigen on tissue microarrays containing paraffin-embedded tissue samples of 199 patients with documented EOC. Patients were operated for ovarian cancer in the period between June 1980 and January 2000.
We observed a rate of Ep-CAM overexpression of 68.8%. Ep-CAM overexpression was significantly related to a decreased overall survival (P = 0.036). The prognostic power of Ep-CAM overexpression was particularly strong in patients with stage III and IV disease. In fact, in this subgroup, median overall survival was twofold higher in patients without as compared to patients with Ep-CAM overexpression (46 vs. 23 months, P < 0.01). Univariate analysis revealed a correlation with histologic grade. We observed a significantly higher rate of Ep-CAM overexpression (83.5%) in grade 3 tumors. Histologic subtypes associated with a higher rate of Ep-CAM overexpression were serous carcinoma, squamous cell carcinoma, undifferentiated carcinoma, clear cell carcinoma, and endometrioid carcinoma. Cox regression analysis showed Ep-CAM overexpression to be an independent prognostic marker (P = 0.037, RR = 1.64).
This retrospective analysis demonstrates for the first time an independent prognostic value of Ep-CAM overexpression in patients with EOC. Ovarian cancer patients with Ep-CAM overexpressing tumors are frequent and would qualify for treatment with Ep-CAM-specific immunotherapeutic approaches.
目前可用的临床和分子因素对上皮性卵巢癌(EOC)患者的预后和预测评估仍不充分。为了确定EOC的潜在分子靶点和预后/预测因素,我们在一项回顾性研究中调查了Ep-CAM过表达在EOC中的预后价值。
我们通过免疫组织化学评估了Ep-CAM抗原在包含199例有记录的EOC石蜡包埋组织样本的组织微阵列上的表达。这些患者在1980年6月至2000年1月期间接受了卵巢癌手术。
我们观察到Ep-CAM过表达率为68.8%。Ep-CAM过表达与总生存率降低显著相关(P = 0.036)。Ep-CAM过表达的预后能力在III期和IV期疾病患者中尤为强大。事实上,在这个亚组中,无Ep-CAM过表达的患者的中位总生存期是有Ep-CAM过表达患者的两倍(46个月对23个月,P < 0.01)。单因素分析显示与组织学分级相关。我们在3级肿瘤中观察到显著更高的Ep-CAM过表达率(83.5%)。与较高Ep-CAM过表达率相关的组织学亚型是浆液性癌、鳞状细胞癌、未分化癌、透明细胞癌和子宫内膜样癌。Cox回归分析显示Ep-CAM过表达是一个独立的预后标志物(P = 0.037,RR = 1.64)。
这项回顾性分析首次证明了Ep-CAM过表达在EOC患者中的独立预后价值。Ep-CAM过表达肿瘤的卵巢癌患者很常见,有资格接受Ep-CAM特异性免疫治疗方法的治疗。